Drug Trial Radar · NCT05248659
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
Last checked: Nov 20, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
600
Planned (sponsor's estimate)
Start
Apr 5, 2022
Primary completion
Dec 28, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Feb 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the long-term safety and tolerability of sibeprenlimab in subjects with IgAN
Conditions
- Immunoglobulin A Nephropathy
Interventions
Sibeprenlimab 400 mg s.c. Q4weeksDrug
Sibeprenlimab 400 mg s.c. q 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: From baseline to the end-of-trial visit in Week 112.
Locations
158 sites in 31 countries. Site status is shown where the registry gives one.
Clinical Research Site #336
Birmingham, Alabama
Clinical Research Site #325
Los Angeles, California
Clinical Research Site #370
Palo Alto, California
Clinical Research Site #330
Denver, Colorado
Clinical Research Site #323
Lauderdale Lakes, Florida
Clinical Research Site #373
Atlanta, Georgia
Clinical Research Site #356
Lawrenceville, Georgia
Clinical Research Site #369
Boston, Massachusetts
Clinical Research Site #331
Worcester, Massachusetts
Clinical Research Site #320
Shelby, Michigan
Clinical Research Site #346
Great Neck, New York
Clinical Research Site #350
Columbus, Ohio
Clinical Research Site #374
Dakota Dunes, South Dakota
Clinical Research Site #324
Houston, Texas
Clinical Research Site #361
Milwaukee, Wisconsin
Clinical Research Site #800
Buenos Aires, Argentina
Clinical Research Site #802
Buenos Aires, Argentina
Clinical Research Site #801
Córdoba, Argentina
Clinical Research Site #011
Liverpool, Australia
Clinical Research Site #003
Garran, Australian Capital Territory, Australia
Clinical Research Site #013
Concord, New South Wales, Australia
Clinical Research Site #014
Kogarah, New South Wales, Australia
Clinical Research Site
New Lambton Heights, New South Wales, Australia
Clinical Research Site #006
Saint Leonards, New South Wales, Australia
Clinical Research Site #012
Adelaide, South Australia, Australia
Clinical Research Site #001
Fitzroy, Victoria, Australia
Clinical Research Site #010
St Albans, Victoria, Australia
Clinical Research Site #401
Genk, Belgium
Clinical Research Site #405
Genk, Belgium
Clinical Research Site #831
Rio de Janeiro, Brazil
Clinical Research Site #823
São Paulo, Brazil
Clinical Research Site #820
Recife, Pernambuco, Brazil
Clinical Research Site #824
Porto Alegre, Rio Grande do Sul, Brazil
Clinical Research Site #821
Joinville, Santa Catarina, Brazil
Clinical Research Site #822
São José do Rio Preto, So Paulo, Brazil
Clinical Research Site #300
Calgary, Alberta, Canada
Clinical Research Site #305
Scarborough Village, Ontario, Canada
CISSS de la Monteregie centre-Centre de recherche Hopital Charles Lemoyne
Greenfield Park, Quebec, Canada
Clinical Research Site #036
Beijing, Beijing Municipality, China
Clinical Research Site #020
Beijing, Beijing Municipality, China
Showing 40 of 158 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.